Research programme: cancer therapeutics - Affibody/Nuclisome
Latest Information Update: 28 Nov 2016
At a glance
- Originator Affibody; Nuclisome AB
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer